Highbridge Capital Management LLC decreased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,920 shares of the biopharmaceutical company’s stock after selling 999 shares during the quarter. Highbridge Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,379,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in ALXN. Jennison Associates LLC lifted its stake in shares of Alexion Pharmaceuticals by 43.1% in the third quarter. Jennison Associates LLC now owns 8,627,536 shares of the biopharmaceutical company’s stock worth $1,199,314,000 after acquiring an additional 2,599,414 shares in the last quarter. FMR LLC increased its holdings in Alexion Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock valued at $2,932,693,000 after buying an additional 1,581,376 shares during the last quarter. American Century Companies Inc. increased its holdings in Alexion Pharmaceuticals by 164.2% in the third quarter. American Century Companies Inc. now owns 1,904,296 shares of the biopharmaceutical company’s stock valued at $264,716,000 after buying an additional 1,183,476 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Alexion Pharmaceuticals by 7,677.7% in the second quarter. Advisors Asset Management Inc. now owns 1,155,454 shares of the biopharmaceutical company’s stock valued at $2,288,000 after buying an additional 1,140,598 shares during the last quarter. Finally, Iridian Asset Management LLC CT increased its holdings in Alexion Pharmaceuticals by 58.1% in the third quarter. Iridian Asset Management LLC CT now owns 2,365,078 shares of the biopharmaceutical company’s stock valued at $328,769,000 after buying an additional 868,886 shares during the last quarter. Institutional investors and hedge funds own 93.33% of the company’s stock.
ALXN has been the subject of several research analyst reports. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Barclays boosted their price objective on Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a report on Friday, September 28th. BidaskClub raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 29th. Credit Suisse Group set a $156.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. Finally, Morgan Stanley boosted their price objective on Alexion Pharmaceuticals from $157.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $161.50.
In other news, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total transaction of $307,728.65. Following the completion of the transaction, the executive vice president now directly owns 29,304 shares of the company’s stock, valued at $3,461,681.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.35% of the stock is currently owned by corporate insiders.
NASDAQ:ALXN opened at $115.60 on Friday. The company has a market cap of $27.00 billion, a PE ratio of 18.48, a P/E/G ratio of 1.04 and a beta of 1.02. Alexion Pharmaceuticals, Inc. has a 52 week low of $102.10 and a 52 week high of $140.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The business’s revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.44 earnings per share. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Position Lowered by Highbridge Capital Management LLC” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://transcriptdaily.com/2018/12/08/alexion-pharmaceuticals-inc-alxn-position-lowered-by-highbridge-capital-management-llc.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Article: Analyst Ratings
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.